Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors.

Abstract A new series of 32 pyrimido- and 5 tetrahydropyrazino[2,1- f ]purinediones was obtained and evaluated for their adenosine receptors (ARs) affinities. The 1,3-dibutyl derivative of 9-(4-(2-(dimethylamino)ethoxy)phenyl)-6,7,8,9-tetrahydropyrimido[1,2 -f ]purine-2,4(1 H ,3 H )-dione was found to be the most potent A 1 AR antagonist of the present series, showing selectivity over the other AR subtypes. The structure–activity for the obtained purinediones was established. Docking experiments of the investigated library to homology models of the human and rat A 1 and A 2A ARs allowed to compare the expected binding modes for selected compounds. The detailed analysis of binding cavities within individual AR subtypes indicated small but significant structural variations that may underlie the observed differences in binding affinities of purinediones at particular subtypes and species.